Indication

Lialda is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.

Important Safety Information

  • Lialda is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of Lialda.
  • Renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported with products such as Lialda that contain mesalamine or are converted to mesalamine. It is recommended that patients have an evaluation of renal function prior to initiating use of Lialda and periodically while on therapy. Exercise caution when using Lialda in patients with known renal dysfunction or a history of renal disease.

Read More Below

This site is intended for US health care professionals. Patient Site
For active, mild to moderate ulcerative colitis (UC)

Important Safety Information

Lialda is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of Lialda. See Important Safety Information

Lialda® (mesalamine): #1 Prescribed 5-ASA Among Gastroenterologists1

UC Patient Profiles

5-ASAs are an ACG-recommended first-line therapy option for appropriate patients with active, mild to moderate UC.1 As you consider Lialda for your appropriate patients, explore the profiles below.

1

Newly diagnosed, mild UC

Sarah:

Student, 21,
Newly Diagnosed, Mild UC

Colonoscopy Findings2,3:

Erythema, minimal granularity, decreased vascular pattern

Rectal Bleeding2:

Streaks of blood

Stool Frequency2:

(More than usual/day) 1-2

2

Newly diagnosed, moderate UC

Daniel:

Teacher, 28,
Newly Diagnosed, Moderate UC

Colonoscopy Findings2,3:

Marked erythema, granularity, absent vascular pattern, bleeding with minimal trauma, friability, no ulcerations

Rectal Bleeding2:

Obvious blood

Stool Frequency2:

(More than usual/day) 3-4

3

Flaring, mild UC

Scott:

Accountant, 50,
Flaring with Mild UC

Colonoscopy Findings2,3:

Erythema, minimal granularity, decreased vascular pattern

Rectal Bleeding2:

Streaks of blood

Stool Frequency2:

(More than usual/day) 1-2

4

Flaring, moderate UC

Beth:

Nurse, 45,
Flaring with Moderate UC

Colonoscopy Findings2,3:

Marked erythema, granularity, absent vascular pattern, bleeding with minimal trauma, friability, no ulcerations

Rectal Bleeding2:

Obvious blood

Stool Frequency2:

(More than usual/day) 3-4

5

Maintaining UC remission

Alan:

Chef, 58,
In UC Remission (Original Diagnosis: Moderate UC)

Colonoscopy Findings (at Diagnosis)2,3:

Marked erythema, granularity, absent vascular pattern, bleeding with minimal trauma, friability, no ulcerations

Rectal Bleeding (at Diagnosis)2:

Obvious blood

Stool Frequency (at Diagnosis)2:

(More than usual/day) 3-4

Follow-Up Colonoscopy4:

Normal Mucosal Appearance, Intact Vascular Pattern, No Friability Or Granulation

Follow-Up Visit 2 Months Later2:

In remission, not currently on treatment


In a randomized, double-blind, non-inferiority, active comparator trial in 826 patients with UC in remission, 83.7% of patients taking Lialda 2.4 g once daily maintained remission at Month 6 vs 81.5% on the comparator (mesalamine delayed release 1.6 g/day (0.8 g twice daily). Maintaining endoscopic remission was defined as a modified UC-DAI endoscopy subscore of ≤1.

Scoring criteria for endoscopic (mucosal) appearance: 0 (normal), 1 (mild: no friability, erythema, minimal granularity, decreased vascular pattern).

Actor portrayals.
Hypothetical patient profiles.

Back to top Back to top

Back to top Back to top